The Bull Rankings scorecard — our quality-growth score is 83.8 / 100, built from three pillars each graded 0–100 against sector peers: Quality 88, Growth 94, Value 72. At today's price, our reverse-DCF read says the market is implicitly betting on about 28% a year in free-cash-flow growth sustained for a decade — a gauge of how much optimism is already in the stock.
The thesis
CareDx is a high‑growth, high‑quality compounder that the market is already pricing aggressively. As of the quarter ended June 30 2026 the stock trades at $38.1, just 6 % below its 52‑week high of $40.47, while revenue surged 34.4% YoY. Our model awards an 83.8/100 quality‑growth score, driven by a Growth pillar of 94 and a Quality pillar of 88—both well above sector peers. The only blemish is a Value pillar of 72, reflecting a premium valuation. The reverse‑DCF built into the Bull Rankings model implies the market expects ~28% annual free‑cash‑flow growth for a decade. That assumption outstrips the 34.4% revenue growth we see now, meaning the price already embeds a hefty optimism about sustained cash generation. With a ROE of 26.1% and profit margin of 24.2%, the business is turning profits at a rate that can fund that growth without external capital. In short, the strongest pillar (Growth) justifies a buy, but the weak Value pillar warns the price may be stretched. The thesis: own CDNA now, but be ready to trim if the implied 28% FCF trajectory proves unrealistic.
What the business actually is
CareDx sells transplant‑monitoring diagnostics that let clinicians detect organ injury before it becomes irreversible. Its flagship AlloSure Kidney measures donor‑derived cell‑free DNA (dd‑cfDNA) to flag early rejection in kidney recipients. The AlloMap Heart gene‑expression panel and AlloSure Heart dd‑cfDNA test serve heart transplants, while AlloSure Lung does the same for lung grafts. The HeartCare platform interprets these signals into actionable categories—immune quiescence, active injury, acute cellular rejection, and antibody‑mediated rejection—giving physicians a clear roadmap. The primary customers are transplant centers and hospital labs across the United States and abroad, with the kidney segment historically delivering the bulk of revenue and now the lung and heart lines accelerating.
Why it can keep compounding
Margins of 24.2% and a ROE of 26.1% show the business extracts strong returns on capital, a hallmark of a quality franchise. The moat stems from the proprietary dd‑cfDNA technology, which requires sophisticated assay development and regulatory clearance—barriers that keep competitors at bay. Moreover, the data‑rich HeartCare analytics create a sticky relationship with clinicians; once a center adopts the platform, switching costs are high because longitudinal patient data are embedded in the system. Our model flags stock buybacks as a positive signal, indicating management believes the shares are undervalued relative to intrinsic cash generation. With a debt‑to‑equity of just 0.08, the balance sheet is lean, giving the company room to reinvest in R&D or expand into new organ markets without diluting shareholders.
The valuation question
At $38.1 the stock trades at a price‑to‑sales multiple of 4.3, which is modest for a biotech‑diagnostics firm but still above the sector average of roughly 3.0. The reverse‑DCF suggests the market is pricing in ~28% yearly free‑cash‑flow growth for ten years. Compare that to the 34.4% YoY revenue growth we just reported; the implied FCF growth is actually lower than the current revenue trajectory, implying the market is already generous on cash conversion and margin stability. However, the Value pillar of 72 signals that, relative to peers, the stock is on the expensive side—perhaps because investors are already betting on continued high‑margin expansion and the upcoming rollout of AlloSure Lung. If the company can keep margins near 24% while scaling, the 28% FCF assumption is plausible. If margins erode or growth slows, the price will look overvalued.
The bear case
Skeptics point to the beta of 2.43, meaning the stock is far more volatile than the market—any miss on growth could trigger outsized downside. The analyst consensus 1‑yr target of $35.4 sits below today’s price, indicating that even the buy‑side expects a modest correction. Recent news that BlackRock disclosed a 9% beneficial stake (Stock Titan) could be interpreted as a signal that a large institutional player sees upside, but it also raises the specter of a future sell‑down that could pressure the share price. The weakest pillar—Value—suggests the market is already paying a premium; a single quarter of slower revenue growth or a margin dip would make the 28% implied FCF growth look unattainable, prompting a sharp re‑rating.
What would change our mind
First, a quarterly revenue growth slowdown to below 20% would break the link between current growth and the 28% FCF assumption, flipping the thesis to bearish. Second, if profit margin fell under 20%—a drop of more than 4 percentage points—our Quality score would erode, and the Value pillar would become even weaker. Third, any increase in debt‑to‑equity above 0.2 would signal balance‑sheet strain, undermining the buy‑back signal and raising the cost of capital. Until one of those triggers appears, the upside from a high‑quality, high‑growth franchise outweighs the premium already baked into the price.